This study supports the model that GSK3 inhibition activates NF-κB, which leads to TNF-α production, induction of cell surface receptors, enhanced conjugate formation and subsequent AML cell killing (Fig. 6d). This evidence concerns the gene TNF and acute myeloid leukemia.